University of South Florida

Digital Commons @ University of South Florida
Neurosurgery and Brain Repair Faculty
Publications

Neurosurgery and Brain Repair

2019

A Hallmark Clinical Study of Cord Blood Therapy in Adults with
Ischemic Stroke
Paul R. Sanberg
University of South Florida, psanberg@usf.edu

Jared Ehrhart
Saneron CCEL Therapeutics

Follow this and additional works at: https://digitalcommons.usf.edu/nbr_facpub
Part of the Neurosurgery Commons

Scholar Commons Citation
Sanberg, Paul R. and Ehrhart, Jared, "A Hallmark Clinical Study of Cord Blood Therapy in Adults with
Ischemic Stroke" (2019). Neurosurgery and Brain Repair Faculty Publications. 26.
https://digitalcommons.usf.edu/nbr_facpub/26

This Article is brought to you for free and open access by the Neurosurgery and Brain Repair at Digital Commons @
University of South Florida. It has been accepted for inclusion in Neurosurgery and Brain Repair Faculty
Publications by an authorized administrator of Digital Commons @ University of South Florida. For more
information, please contact scholarcommons@usf.edu.

Commentary

A Hallmark Clinical Study of Cord Blood
Therapy in Adults with Ischemic Stroke

Cell Transplantation
2019, Vol. 28(9-10) 1329–1332
ª The Author(s) 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0963689719854354
journals.sagepub.com/home/cll

Paul R. Sanberg1 and Jared Ehrhart2

Abstract
The therapeutic application of human umbilical cord blood cells has been an area of great interest for at least the last 25 years.
Currently, cord blood cells are approved for reconstitution of the bone marrow following myeloablation in both young and
old patients with myeloid malignancies and other blood cancers. Translational studies investigating alternative uses of cord
blood have also shown that these cells not only stimulate neurogenesis in the aged brain but are also potentially therapeutic in
the treatment of adult neurodegenerative disorders including amyotrophic lateral sclerosis, Alzheimer’s disease, ischemic
stroke, traumatic brain injury, and Parkinson’s disease. Recent advances in the clinical application of cord blood cells by Dr.
Joanne Kurtzberg and colleagues have found that non-HLA matched allogeneic banked cord blood units in immunocompetent
patients with ischemic stroke are safe and well tolerated. Although the exact mechanism(s) of action that provide the beneficial effects observed from a cord blood cell-based therapy are currently unknown, several studies using models of neurodegenerative disease have shown these cells are immune-modulatory and anti-inflammatory. Thus, any future clinical studies
investigating the efficacy of this cord blood cell therapeutic would strongly benefit from the inclusion of methodologies to
determine changes in both markers of inflammation and the response of immune tissues, such as the spleen, in subjects
receiving cell infusion.
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A recent clinical study by Joanne Kurtzberg with her colleagues at Duke University, and the University of Texas has
opened the door for further clinical investigation into the
application of cord blood cells as a therapeutic treatment for
adult neurodegenerative disorders 1 . The study, titled
“Allogeneic Umbilical Cord Blood Infusion for Adults with
Ischemic Stroke: Clinical Outcomes from a Phase I Safety
Study,” is a hallmark clinical study using non-human leukocyte antigen (HLA) matched cord blood units for the treatment of ischemic stroke in immunocompetent adult patients
(CoBIS).
The therapeutic application of human umbilical cord
blood cells has been an area of great interest for at least the
last quarter of a century, with the first clinical infusion of
cells derived from cord blood being used to treat juvenile
Fanconi’s anemia in 19882, to more current applications to
treat myeloid malignancies in children. Recent clinical studies have investigated the alternative application of cord
blood to treat other childhood-related neurological disorders
such as cerebral palsy3,4, autism spectrum disorder5, and
lysosomal or peroxisomal storage diseases6. Early basic
research and translational studies from our group, which date

back almost two decades, have also shown that cord blood
cells can not only stimulate neurogenesis in the aged brain7
but are also potentially therapeutic in the treatment of adult
neurodegenerative disorders including amyotrophic lateral
sclerosis (ALS)8,9, Alzheimer’s disease (AD)10,11, ischemic
stroke12–14, traumatic brain injury (TBI)15–17, and Parkinson’s disease (PD)18. In addition, many of these studies have
highlighted a unique property that exists for cord blood cellbased therapies in neurodegenerative diseases: the nonnecessity for HLA matching or immunosuppression. Many
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early studies exploring the therapeutic potential of cord
blood cells in animal models of neurodegenerative disorders
employed cyclosporine or some other immunosuppressant to
reduce the probability of developing of graft versus host
disease (GvHD), and graft rejection8,9,19. Later studies found
this practice to be unnecessary, with reports showing that the
therapeutic effects of cord blood cell infusion remained the
same with no incidence of GvHD in animals where immunosuppression was omitted10,11. The lack of need for HLA
matching and low immunogenicity of this particular cell
population results in the ability to treat cord blood cell therapy in the same regard as a simple blood transfusion. This
phenomenon is mostly due to the relative immaturity of
these cells in relation to inflammation and the immune
response, and makes them good candidates to treat many
of the aforementioned neurodegenerative diseases20. While
a decade has passed since much of this original work was
performed, it has provided the foundation for this clinical
study as well as others which have aided in furthering the
development of cord blood cells as a therapy for neurological disorders.
CoBIS is a phase I open-label study which investigates
the safety and tolerability of non-HLA matched allogeneic
banked cord blood units in immunocompetent patients of
ischemic stroke. The study enrolled 10 male patients who
were infused with cord blood cells at 3–9 days post the stroke
event, and monitored for 12 months post treatment. Each
participant completed the study with no apparent incidence
of GvHD or other unexpected adverse reactions that could be
directly attributed to the infusion of cord blood. In addition,
all participants displayed improvement in the modified Rankin Score and the National Institutes of Health Stroke Scale,
indicating a recovery of both neurological and physical function. Overall the study found that infusion of non-HLA
matched allogeneic cord blood in adults that have been
recently experienced ischemic stroke is safe and well
tolerated.
While the primary endpoint of this phase I trial was to
determine the safety of cord blood infusion in subjects with
ischemic stroke, the authors do suggest several potential
mechanisms for the efficacy that was also observed. They
refer to animal studies that have shown the migration of
infused cells to sites of injury in the central nervous system
(CNS) and the production of trophic factors that aid in
repair21, but fail to address a key factor where cord blood
therapy has shown to have a significant impact: the migration of endogenous immune cells from the periphery and
resultant inflammation. This phenomenon occurs shortly
after the stroke event, and ultimately leads to exacerbation
of both neurological and physical disability. Translational
studies in animals using a middle cerebral artery occlusion
(MCAO) model of ischemic stroke have shown that the efficacy of cord blood primarily stems from peripheral antiinflammatory effects that reduce cell death and disease
pathology within the CNS13,22. These studies have shown
significant reduction in infarct volume, mainly due to the
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prevention of cell loss within the penumbral tissue surrounding the core of the stroke. Without therapeutic intervention
the tissue in the penumbra becomes hypoxic and extremely
sensitive to inflammatory insult, which can result in cell
death occurring days to weeks after the ischemic event. Vendrame et al. 23 were the first to detail that the antiinflammatory effects of cord blood therapy in ischemic
stroke are primarily due to inhibition of the peripheral splenic immune response to the damage that has occurred in the
CNS. This study observed a significant reduction in spleen
volume occurring shortly after the ischemic insult in
untreated animals. Another cohort receiving an intravenous
injection of cord blood cells, after MCAO, resulted in retention of the normotypic spleen size and shape with significant
reduction in neurodegeneration in the penumbra. Since this
dynamic change in spleen size has also been observed in
patients of ischemic stroke24, the inclusion of this phenomenon as a secondary outcome in future clinical studies might
be beneficial in determining efficacy of the cord blood infusion. This could be easily documented using either ultrasound or CT technologies, and could potentially provide
additional clinical evidence of the anti-inflammatory nature
of the cord blood cell-based therapy.
In addition, even though the inclusion criteria of this
phase I study did allow for female subjects to participate,
it seems somewhat odd that only male patients were
enrolled. This is not necessarily a fault of the current study,
since it is only determining the overall safety of cord blood
therapy in ischemic stroke, but could be a detriment in future
clinical studies if they are unable to enroll a representative
population of female participants. Translational studies have
reported significant differences in sex-specific responses to
ischemic injury, with alterations in inflammation and potential regeneration between males and females25.
There have been a number of studies that have also investigated a combination of cord blood cells with blood brain
permeabilizers, such as mannitol, in attempts to increase the
efficacy of this particular therapy. One pre-clinical study in
particular has shown that co-administration of cord blood
with mannitol has shown greater efficacy compared with
cord blood infusion alone26. This therapeutic combination
results in not only the ability to reduce the cell dose while
increasing therapeutic efficacy, but also results in a significant increase in the number of stem cells that enter the brain
to promote regeneration and repair27. In addition, this combinatorial infusion of cord blood cells and mannitol increases
the effective therapeutic window of cord blood cell infusion
and allows for the treatment of chronic cases of ischemic
stroke26. Future clinical work that employs this combination
may show improve the therapeutic efficacy and, due to lower
cell numbers needed per infusion, allow for multiple doses to
be provided from the same cord blood unit to treat a patient
with ischemic stroke.
Overall, this recent clinical study (Laskowitz et al.1)
shows that the infusion of non-HLA matched allogeneic cord
blood is safe and well tolerated in patients of ischemic
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stroke. Future studies investigating the efficacy of this cord
blood therapeutic would strongly benefit from the inclusion
of methodologies to determine changes in the spleen size of
ischemic stroke patients. Determining this outcome could
provide significant clinical evidence to one of the potential
mechanisms of action for cord blood therapy. In addition, the
inclusion of a representative population of female participants is needed to fully ascertain the therapeutic efficacy for
both sexes. The therapeutic efficacy observed from cord
blood cells in this clinical trial makes it a good candidate
to help individuals impacted by hemorrhagic stroke as
well28. While this study is the most recent step in the clinical
advancement of cord blood therapy for age-related neurodegenerative disorders, additional clinical studies may now be
possible to test the safety and potential efficacy in a wide
range of other indications such as ALS, AD, TBI, and PD. A
phase II double-blind placebo-controlled study investigating
non-HLA matched cord blood therapy in ischemic stroke
(CoBIS 2 - NCT03004976) is currently underway and we
are anxiously awaiting the results29.
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